US Bancorp
- SEC CIK
- 0000036104
- Latest filing
- Aug 12, 2026
ENTA holding history
Enanta Pharmaceuticals Inc in every 13F filed by US Bancorp, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
ENTA overviewAll 13F holders of ENTAFull Q2 2026 holdings
- Shares (Q3 2025)
- 0
- Sold out in Q3 2025
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 17
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q3 2025 | 0 | $0 | 0.0% | −5,916−100.0% | Sold out | Holders |
| Q2 2025 | 5,916 | $44.7K | <0.1% | −584−9.0% | Reduced | Holders |
| Q1 2025 | 6,500 | $35.9K | <0.1% | +6,500 | New | Holders |
| Q4 2024 | 0 | $0 | 0.0% | −4,329−100.0% | Sold out | Holders |
| Q3 2024 | 4,329 | $44.8K | <0.1% | +4,243+4,933.7% | Added | Holders |
| Q2 2024 | 86 | $1.11K | <0.1% | −832−90.6% | Reduced | Holders |
| Q1 2024 | 918 | $16.0K | <0.1% | −3,269−78.1% | Reduced | Holders |
| Q4 2023 | 4,187 | $39.4K | <0.1% | +3,263+353.1% | Added | Holders |
| Q3 2023 | 924 | $10.3K | <0.1% | +800+645.2% | Added | Holders |
| Q2 2023 | 124 | $2.65K | <0.1% | −240−65.9% | Reduced | Holders |
| Q1 2023 | 364 | $14.7K | <0.1% | −7−1.9% | Reduced | Holders |
| Q4 2022 | 371 | $17.3K | <0.1% | −19−4.9% | Reduced | Holders |
| Q3 2022 | 390 | $20.0K | <0.1% | +46+13.4% | Added | Holders |
| Q2 2022 | 344 | $16.0K | <0.1% | +158+84.9% | Added | Holders |
| Q1 2022 | 186 | $13.0K | <0.1% | +11+6.3% | Added | Holders |
| Q4 2021 | 175 | $13.0K | <0.1% | +27+18.2% | Added | Holders |
| Q3 2021 | 148 | $8.00K | <0.1% | −869−85.4% | Reduced | Holders |
| Q2 2021 | 1,017 | $45.0K | <0.1% | −168−14.2% | Reduced | Holders |
| Q1 2021 | 1,185 | $58.0K | <0.1% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.